• Highlight progress in understanding the pathogenesis and diagnosis of MDS and AA • Revisit emerging efforts to optimize comprehensive care in the management of MDS and AA including guideline updates • Illustrate the optimal use of iron chelation therapy for MDS and AA patients in clinical practice • Discuss the role of thrombopoietin receptor agonists in the management of patients with severe AA